Publication of 2023 Annual Report & Notice of AGM

BiVictriX Therapeutics PLC

26 June 2024

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

Publication of 2023 Annual Report and Notice of AGM

Alderley Park, 26 June 2024 - BiVictriX Therapeutics plc (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst eliminating treatment-related toxicities, announces that it has published and posted to shareholders the annual report and financial statements for the year ended 31 December 2023 ("Annual Report and Accounts"), and Notice of Annual General Meeting ("AGM").

BiVictriX will hold its AGM at the Company's registered office at Mereside Alderley Park, Alderley Edge, Manchester, SK10 4TG on 24 July 2024 at 3.00 p.m. (BST).

The Annual Report and Accounts and Notice of AGM are also available to view on, and download from, the Company's website at https://www.bivictrix.com/investor-centre.

ENDS For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Michael Kauffman, Non-Executive Chairman Email: [e-mail] SP Angel Corporate Finance LLP (NOMAD and Broker)   Tel: [phone] David Hignell, Caroline Rowe, Kasia Brzozowska (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Gordon (UK) Limited (Joint Broker)   Tel: [phone] Rupert Dearden/Freddy Crossley/Emma Earl ICR Consilium Mary-Jane Elliott, Namrata Taak, Max Bennett, Emmalee Hoppe Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com  

 

END